Terms: = Prostate cancer AND ERG, P11308, 2078 AND Diagnosis
177 results:
1. Transcription Factors in prostate cancer: Insights for Disease Development and Diagnostic and Therapeutic Approaches.
Silva KCS; Tambwe N; Mahfouz DH; Wium M; Cacciatore S; Paccez JD; Zerbini LF
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674385
[TBL] [Abstract] [Full Text] [Related]
2. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
3. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
4. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
5. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract] [Full Text] [Related]
6. New Molecular Markers for prostate cancer diagnosis.
Amiri M; Asadi Samani L; Kashi AH; Khadem N; Ziaee SAM; Mowla SJ
Urol J; 2024 Feb; 21(1):1-13. PubMed ID: 37818554
[TBL] [Abstract] [Full Text] [Related]
7. Immunohistochemical Expression of Alpha-Methyl-Coa (AMACR) and erg in Prostatic Adenocarcinoma and Prostatic Hyperplasia: A Comparative Study.
Sayed RMS; El Shorbagy G; Shibel PEE
Asian Pac J Cancer Prev; 2023 Aug; 24(8):2861-2868. PubMed ID: 37642075
[TBL] [Abstract] [Full Text] [Related]
8. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract] [Full Text] [Related]
9. Associations between Etiologic or Prognostic Tumor Tissue Markers and Neighborhood Contextual Factors in Male Health Professionals Diagnosed with prostate cancer.
Iyer HS; Kensler KH; Vaselkiv JB; Stopsack KH; Roscoe C; Bandera EV; Qin B; Jang TL; Lotan TL; James P; Hart JE; Mucci LA; Laden F; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2023 Aug; 32(8):1120-1123. PubMed ID: 37249585
[TBL] [Abstract] [Full Text] [Related]
10. Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens.
Schafer C; Young D; Singh H; Jayakrishnan R; Banerjee S; Song Y; Dobi A; Petrovics G; Srivastava S; Srivastava S; Sesterhenn IA; Chesnut GT; Tan SH
J Immunol Methods; 2023 Jul; 518():113493. PubMed ID: 37196930
[TBL] [Abstract] [Full Text] [Related]
11. Clinical Characteristics and Survival Analysis of Patients With Second Primary Malignancies After Hepatocellular Carcinoma Liver Transplantation: A SEER-based Analysis.
Ding Q; Wang K; Li Y; Peng P; Zhang D; Chang D; Wang W; Ren L; Tang F; Li Z
Am J Clin Oncol; 2023 Jul; 46(7):284-292. PubMed ID: 37145881
[TBL] [Abstract] [Full Text] [Related]
12. Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential.
Ragavi R; Muthukumaran P; Nandagopal S; Ahirwar DK; Tomo S; Misra S; Guerriero G; Shukla KK
Urol Oncol; 2023 Aug; 41(8):340-353. PubMed ID: 37032230
[TBL] [Abstract] [Full Text] [Related]
13. Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk.
Cussenot O; Renard-Penna R; Montagne S; Ondet V; Pilon A; Guechot J; Comperat E; Hamdy F; Lamb A; Cancel-Tassin G
BJU Int; 2023 Jun; 131(6):745-754. PubMed ID: 36648168
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of automatic discrimination between benign and malignant prostate tissue in the era of high precision digital pathology.
Zhdanovich Y; Ackermann J; Wild PJ; Köllermann J; Bankov K; Döring C; Flinner N; Reis H; Wenzel M; Höh B; Mandel P; Vogl TJ; Harter P; Filipski K; Koch I; Bernatz S
BMC Bioinformatics; 2023 Jan; 24(1):1. PubMed ID: 36597019
[TBL] [Abstract] [Full Text] [Related]
15. Differences in prostate cancer Transcriptomes by Age at diagnosis: Are Primary Tumors from Older Men Inherently Different?
Zhou CD; Pettersson A; Plym A; Tyekucheva S; Penney KL; Sesso HD; Kantoff PW; Mucci LA; Stopsack KH
Cancer Prev Res (Phila); 2022 Dec; 15(12):815-825. PubMed ID: 36125434
[TBL] [Abstract] [Full Text] [Related]
16. B7-H3 as a Therapeutic Target in Advanced prostate cancer.
Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
[TBL] [Abstract] [Full Text] [Related]
17. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
18. [Urinary biomarkers in the diagnosis of prostate cancer.].
Ballesteros Ruiz C; Álvarez-Maestro M; Aguilera Bazán A; Martínez-Piñeiro L
Arch Esp Urol; 2022 Mar; 75(2):165-172. PubMed ID: 35332886
[TBL] [Abstract] [Full Text] [Related]
19. [Clinicopathological Features and Expression of P504s,E-cadherin,Erythroblast Transformation-specific Related Gene and Estrogen Receptor in prostate Adenocarcinoma in Tibet].
Luo HH; Huo Z; Xiao Y; Nimazhuoma ; Wang Q; Dazhen ; Cirenquzhen
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):761-766. PubMed ID: 34728038
[TBL] [Abstract] [Full Text] [Related]
20. prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study.
Yamoah K; Asamoah FA; Abrahams AOD; Awasthi S; Mensah JE; Dhillon J; Mahal BA; Gueye SM; Jalloh M; Farahani SJ; Lal P; Rebbeck TR; Yarney J
Prostate; 2021 Dec; 81(16):1402-1410. PubMed ID: 34529278
[TBL] [Abstract] [Full Text] [Related]
[Next]
